AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 400/200mg
Number of subjects: 1064
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50mg
Number of subjects: 1064
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100mg
Number of subjects: 1064
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (any dose)
Number of subjects: 1064
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100mg with immunomodulators
Number of subjects: 1064
Study 27440869 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50mg with immunomodulators
Number of subjects: 1064
Study 24636129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker shoes
Number of subjects: 13
Study 24636129 — intervention group
Group type: COMPARATOR
Intervention: Standard running shoes
Number of subjects: 13
Study 23942480 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma TIPS Internet intervention
Number of subjects: 300
Study 23942480 — intervention group
Group type: COMPARATOR
Intervention: No early intervention (control)
Number of subjects: 300
Study 21571170 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered closure
Number of subjects: 38
Study 21571170 — intervention group
Group type: COMPARATOR
Intervention: Buried sutures and adhesive strips
Number of subjects: 38
Study 19171629 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulant medications for ADHD
Number of subjects: 743
Study 19171629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 743
Study 22854901 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine up to 600 mg/day
Number of subjects: 46
Study 22854901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15699750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 15699750 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 0
Study 12617742 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 ml contrast material injected before CT scan (group 1; n=7)
Number of subjects: 14
Study 12617742 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 ml contrast material injected before CT scan (group 2; n=7)
Number of subjects: 14
Study 10534749 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence photodetection using violet light (lambda = 375 to 440 nm)
Number of subjects: 49
Study 10534749 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrophotometric analysis in the green spectral range
Number of subjects: 49
Study 8564635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% hydralazine
Number of subjects: 20
Study 8564635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hydralazine
Number of subjects: 20
Study 8564635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2108884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day leuprorelin given subcutaneously plus 250 mg flutamide three times a day
Number of subjects: 603
Study 2108884 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/day leuprorelin given subcutaneously
Number of subjects: 603
Study 2108884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of leuprorelin and flutamide
Number of subjects: 603
Study 2108884 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin plus placebo
Number of subjects: 603
Study 6446008 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 0.50 mg by aerosol inhalation
Number of subjects: 20
Study 6446008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.04 mg by aerosol inhalation
Number of subjects: 20
Study 12529069 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 135
Study 12529069 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 135
Study 12529069 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 31179798 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (25‐30 Hz, 2 mm amplitude, 10 repetitions (30‐60 s) with 1 min rest, 15‐20 min/day, 3 days/week for 24 weeks)
Number of subjects: 39
Study 31179798 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical treatment and physical therapy program)
Number of subjects: 39
Study 31847717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month treatment with inhaled budesonide (200 μg, twice daily)
Number of subjects: 101
Study 31847717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month treatment with inhaled budesonide (200 μg, twice daily)
Number of subjects: 101
Study 31847717 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month treatment with inhaled budesonide (200 μg, twice daily)
Number of subjects: 101
Study 29413236 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossBoss catheter
Number of subjects: 246
Study 29413236 — intervention group
Group type: COMPARATOR
Intervention: Wire escalation
Number of subjects: 246
Study 27803234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-tricalcium phosphate (HATCP) graft
Number of subjects: 11
Study 27803234 — intervention group
Group type: COMPARATOR
Intervention: Autologous iliac crest bone graft (autograft)
Number of subjects: 11
Study 25012275 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice (1 hour daily for 3 months)
Number of subjects: 3
Study 22186772 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 0
Study 22186772 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0
Study 20483664 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (100 mug)
Number of subjects: 396
Study 20483664 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (150 IU daily for 7 days)
Number of subjects: 396
Study 17917554 — intervention group
Group type: COMPARATOR
Intervention: Risperidone alone
Number of subjects: 33
Study 17917554 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus valproate
Number of subjects: 33
Study 16271907 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone 2.5 mg/day
Number of subjects: 373
Study 16271907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 11896130 — intervention group
Group type: EXPERIMENTAL
Intervention: Health walks group
Number of subjects: 260
Study 11896130 — intervention group
Group type: COMPARATOR
Intervention: Advice only group
Number of subjects: 260
Study 10451805 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP), 5 mg every 8 hours for 2 months
Number of subjects: 22
Study 10451805 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered every 8 hours for 2 months
Number of subjects: 22
Study 7598054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistant starch diet (39.0 +/- 3.0 g/d)
Number of subjects: 11
Study 7598054 — intervention group
Group type: COMPARATOR
Intervention: Low-resistant starch diet (5.0 +/- 0.4 g/d)
Number of subjects: 11
Study 2113661 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 32
Study 2113661 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 32
Study 115562 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (50 ml/kg of amino acid solution with 10 or 25 g/dl glucose plus 500 ml of soybean emulsion for 24 hours before and 5 days after operation)
Number of subjects: 47
Study 115562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 47
Study 31353177 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine 0.1 mg (group M+)
Number of subjects: 176
Study 31353177 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block using 0.3% ropivacaine (0.45 mL/kg each side, maximum 150 mg) (group pQ+)
Number of subjects: 176
Study 31353177 — intervention group
Group type: COMPARATOR
Intervention: Spinal saline (M-)
Number of subjects: 176
Study 31353177 — intervention group
Group type: COMPARATOR
Intervention: Saline (pQ-)
Number of subjects: 176
Study 29089009 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (coalition building)
Number of subjects: 1018
Study 29089009 — intervention group
Group type: COMPARATOR
Intervention: Program technical assistance (Resources for Services)
Number of subjects: 1018
Study 26323451 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP) with adjunctive Tetracycline Fibers
Number of subjects: 30
Study 26323451 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) alone
Number of subjects: 30
Study 26323451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SRP and SRP with adjunctive Tetracycline Fibers
Number of subjects: 30
Study 24116363 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobon (test group)
Number of subjects: 38
Study 24116363 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Oss (control group)
Number of subjects: 38
Study 24116363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 22091563 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐yearly intravenous (IV) ZOL 5 mg
Number of subjects: 508
Study 22091563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 19331488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 22
Study 19331488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g/kg alcohol
Number of subjects: 22
Study 19331488 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol (placebo)
Number of subjects: 22
Study 19331488 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid cues
Number of subjects: 22
Study 19331488 — intervention group
Group type: EXPERIMENTAL
Intervention: Invalid cues
Number of subjects: 22
Study 16978883 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 8
Study 16978883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12950437 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 12950437 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible inhibitors of monoamine oxidase type A (RIMAs)
Number of subjects: 0
Study 12950437 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (fluvoxamine, paroxetine, sertraline)
Number of subjects: 0
Study 12950437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabergic drugs (clonazepam, gabapentin, pregabalin)
Number of subjects: 0
Study 12950437 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 12950437 — intervention group
Group type: COMPARATOR
Intervention: Buspirone, tricyclics, beta-blockers
Number of subjects: 0
Study 12950437 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine, clonazepam, sertraline, brofaromine
Number of subjects: 0
Study 10952368 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 73
Study 10952368 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEX)
Number of subjects: 73
Study 10952368 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study 8778950 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg bid)
Number of subjects: 219
Study 8778950 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg bid)
Number of subjects: 219
Study 1862787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 0.12 mg/kg
Number of subjects: 103
Study 1862787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 0.20 mg/kg
Number of subjects: 103
Study 1862787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 6612574 — intervention group
Group type: EXPERIMENTAL
Intervention: One minute alcohol cleansing plus application of an antimicrobial film
Number of subjects: 0
Study 6612574 — intervention group
Group type: EXPERIMENTAL
Intervention: One minute alcohol cleansing
Number of subjects: 0
Study 6612574 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial film
Number of subjects: 0
Study 6612574 — intervention group
Group type: COMPARATOR
Intervention: Five minute iodophor scrub
Number of subjects: 0
Study 30869183 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) twice daily
Number of subjects: 543
Study 30869183 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30) twice daily
Number of subjects: 543
Study 28414090 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 417
Study 26687425 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-based scoring system (TNFR1, ST2, Reg3α)
Number of subjects: 492
Study 22941326 — intervention group
Group type: EXPERIMENTAL
Intervention: Office microlaparoscopic ovarian drilling (OMLOD)
Number of subjects: 60
Study 22941326 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic ovarian drilling (LOD)
Number of subjects: 60
Study 22941326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OMLOD and LOD
Number of subjects: 60
Study 21463149 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with sirolimus‐eluting stents
Number of subjects: 600
Study 21463149 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 600
Study 19356233 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes (20 subjects)
Number of subjects: 32
Study 19356233 — intervention group
Group type: COMPARATOR
Intervention: Controls (18 subjects)
Number of subjects: 32
Study 19356233 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes (20 subjects) after HG stress
Number of subjects: 32
Study 19356233 — intervention group
Group type: COMPARATOR
Intervention: Controls (18 subjects) after HG stress
Number of subjects: 32
Study 16341029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal RigiScan
Number of subjects: 43
Study 16341029 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (MIDUS)
Number of subjects: 43
Study 15285979 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cortisol (10 mg/day) for 1 month
Number of subjects: 3
Study 15285979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 11130086 — intervention group
Group type: EXPERIMENTAL
Intervention: Conveen Continence Guard (disposable vaginal device)
Number of subjects: 28
Study 9502664 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 mcg every 4 hours until delivery)
Number of subjects: 38
Study 9502664 — intervention group
Group type: COMPARATOR
Intervention: PGE2 gel (0.5 mg) followed by intravenous oxytocin infusion (Control)
Number of subjects: 38
Study 8062778 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T IUD (TCu.200B)
Number of subjects: 42
Study 8062778 — intervention group
Group type: COMPARATOR
Intervention: Lippes loop IUD
Number of subjects: 42
Study 2898457 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 26830A 50 mg qid
Number of subjects: 43
Study 2898457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31799757 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple counts of goblet cells from high-power fields
Number of subjects: 20
Study 31799757 — intervention group
Group type: EXPERIMENTAL
Intervention: First high-power field counts
Number of subjects: 20
Study 31799757 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent high-power field counts
Number of subjects: 20
Study 31799757 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple counts/individual
Number of subjects: 20
Study 31799757 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative variability (coefficient of variation)
Number of subjects: 20
Study 29659879 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat therapy
Number of subjects: 2
Study 29659879 — intervention group
Group type: COMPARATOR
Intervention: No therapy (off orlistat)
Number of subjects: 2
Study 29132415 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture group
Number of subjects: 42
Study 29132415 — intervention group
Group type: COMPARATOR
Intervention: Minimal acupuncture group
Number of subjects: 42
Study 29132415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Verum and Minimal acupuncture)
Number of subjects: 42
Study 26571891 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum blossom needle tapping therapy at key points combined with Bobath therapy
Number of subjects: 80
Study 26571891 — intervention group
Group type: COMPARATOR
Intervention: Bobath manipulation therapy
Number of subjects: 80
Study 24260334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions, 5 days/week, 60 minutes each, 100% oxygen at 1.5 ATA
Number of subjects: 56
Study 24260334 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 56
Study 21148720 — intervention group
Group type: EXPERIMENTAL
Intervention: rSP-C surfactant (up to eight doses administered over 96 hours)
Number of subjects: 843
Study 21148720 — intervention group
Group type: EXPERIMENTAL
Intervention: rSP-C surfactant
Number of subjects: 843
Study 21148720 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 843
Study 18655738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia test
Number of subjects: 103
Study 17132834 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSkills Workshop + Video
Number of subjects: 196
Study 17132834 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSkills Video
Number of subjects: 196
Study 17132834 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 196
Study 12201321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 1139
Study 12201321 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking while using OCs
Number of subjects: 1139
Study 12201321 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of risks of OC use and smoking
Number of subjects: 1139
Study 12201321 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' personal smoking habits
Number of subjects: 1139
Study 9951781 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 100 mg i.m. every week
Number of subjects: 90
Study 9951781 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 100 mg i.m. every two weeks
Number of subjects: 90
Study 9951781 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 90
Study 9951781 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (both groups)
Number of subjects: 90
Study 8537627 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated cuff (Ag-CC)
Number of subjects: 101
Study 8537627 — intervention group
Group type: COMPARATOR
Intervention: Routine catheter (RC) placements
Number of subjects: 101
Study 1968858 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system for calculating the dose of vaginal prostaglandin E2 tablets
Number of subjects: 110
Study 1968858 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 3 mg vaginal prostaglandin E2 tablets
Number of subjects: 110
Study 380318 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean diet (total substitution of animal proteins)
Number of subjects: 60
Study 380318 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean diet with low P/S ratio (0.1)
Number of subjects: 60
Study 380318 — intervention group
Group type: COMPARATOR
Intervention: Standard low lipid diet
Number of subjects: 60
Study 380318 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean diet with added cholesterol
Number of subjects: 60
Study 380318 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean diet without added cholesterol
Number of subjects: 60
Study 380318 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean diet with high P/S fatty acid ratio
Number of subjects: 60
Study 380318 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean diet for mixed phenotypes (IIB-III)
Number of subjects: 60
Study 380318 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean diet for out-patients
Number of subjects: 60
Study 6831294 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375 per cent bupivicaine
Number of subjects: 30
Study 6831294 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375 per cent bupivicaine and one per cent lidocaine hydrochloride
Number of subjects: 30
Study 6831294 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375 per cent bupivicaine and one per cent carbonated lidocaine
Number of subjects: 30
Study 30623420 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MO3PUFA intake
Number of subjects: 1735
Study 29947083 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg subcutaneously every 4 weeks (n = 68)
Number of subjects: 134
Study 29947083 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 134
Study 27357971 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celecoxib (loading dose the night before surgery then twice daily for 10 days)
Number of subjects: 17
Study 27357971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 24813753 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization for 15 min after IUI
Number of subjects: 391
Study 24813753 — intervention group
Group type: COMPARATOR
Intervention: Immediate mobilization after IUI
Number of subjects: 391
Study 22815387 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h total sleep deprivation (TSD)
Number of subjects: 28
Study 22815387 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (NS)
Number of subjects: 28
Study 20814217 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet gel (PG) applied locally
Number of subjects: 0
Study 20814217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PG)
Number of subjects: 0
Study 20814217 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PG and control)
Number of subjects: 0
Study 17413292 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone infusion (2.3 microg/kg/h)
Number of subjects: 12
Study 17413292 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 16302557 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 873